Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2021-05-28
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX72
|
| gptkbp:brand |
gptkb:Lumykras
|
| gptkbp:CASNumber |
2296729-00-3
|
| gptkbp:chemicalFormula |
C30H30F2N6O3
|
| gptkbp:developedBy |
gptkb:Amgen
|
| gptkbp:form |
gptkb:tablet
120 mg |
| gptkbp:genericName |
gptkb:sotorasib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lumakras
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
KRAS inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
https://www.lumakras.com/prescribing-information
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hepatotoxicity |
| gptkbp:target |
KRAS G12C mutation
|
| gptkbp:bfsParent |
gptkb:sotorasib
|
| gptkbp:bfsLayer |
6
|